Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 7, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2016-10-25
DOI
10.3389/fphar.2016.00395
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Catatonic and Psychotic Symptoms Owing to the Trauma of Captivity in a Cult Environment
- (2017) Sarah E. Dunn et al. PSYCHOSOMATICS
- 460PPHASE I CLINICAL TRIAL OF DS-7423, AN ORAL PI3K/MTOR DUAL INHIBITOR, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
- (2017) T. Yokota et al. ANNALS OF ONCOLOGY
- 1230PDPHASE 1B STUDY OF ORAL DUAL-PI3K/MTOR INHIBITOR GDC-0980 IN COMBINATION WITH CARBOPLATIN (CARBO)/PACLITAXEL (PAC) ± BEVACIZUMAB (BEV) AND CISPLATIN (CIS)/PEMETREXED (PEM) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS AND NSCLC
- (2017) E. Calvo et al. ANNALS OF ONCOLOGY
- First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma.
- (2017) D. S. Tan et al. JOURNAL OF CLINICAL ONCOLOGY
- A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.
- (2017) A. J. Wagner et al. JOURNAL OF CLINICAL ONCOLOGY
- The Phosphoinositide-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer
- (2017) Josh Lauring et al. Journal of the National Comprehensive Cancer Network
- Nivolumab for Refractory Anaplastic Large Cell Lymphoma: A Case Report
- (2016) Holger Hebart et al. ANNALS OF INTERNAL MEDICINE
- Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma
- (2016) Emmanuel Seront et al. BJU INTERNATIONAL
- Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
- (2016) Dai Maruyama et al. CANCER SCIENCE
- A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer
- (2016) Thomas Powles et al. EUROPEAN UROLOGY
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- Erratum: The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells
- (2016) R Thijssen et al. LEUKEMIA
- CIK immunotherapy in refractory hematologic malignancies
- (2016) Eric Wong et al. LEUKEMIA RESEARCH
- Genomic complexity of multiple myeloma and its clinical implications
- (2016) Salomon Manier et al. Nature Reviews Clinical Oncology
- Phase II study of everolimus in refractory testicular germ cell tumors
- (2016) Michal Mego et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Repurposing metformin: an old drug with new tricks in its binding pockets
- (2015) R. Pryor et al. BIOCHEMICAL JOURNAL
- mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells
- (2015) Govindasamy-Muralidharan Karthik et al. CANCER LETTERS
- mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR
- (2015) Yancun Yin et al. CELL RESEARCH
- First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
- (2015) B. Basu et al. CLINICAL CANCER RESEARCH
- First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies
- (2015) P. Munster et al. CLINICAL CANCER RESEARCH
- Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives
- (2015) Silvia Ortolani et al. Future Oncology
- PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas
- (2015) DEYU CHEN et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
- (2015) Johanna C. Bendell et al. INVESTIGATIONAL NEW DRUGS
- Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115
- (2015) Deborah S. Mortensen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor CC-223
- (2015) Deborah S. Mortensen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
- (2015) Sara A Hurvitz et al. LANCET ONCOLOGY
- CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization
- (2015) D. S. Mortensen et al. MOLECULAR CANCER THERAPEUTICS
- Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models
- (2015) Giovanni Luca Gravina et al. TUMOR BIOLOGY
- Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study
- (2015) Ulka Vaishampayan et al. UROLOGY
- NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype
- (2014) Seung-Woo Hong et al. APOPTOSIS
- PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
- (2014) HaiXia Li et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
- (2014) Jasmeet Chadha Singh et al. BREAST CANCER RESEARCH
- Rab1A Is an mTORC1 Activator and a Colorectal Oncogene
- (2014) Janice D. Thomas et al. CANCER CELL
- PI3K/mTOR Dual Inhibitor VS-5584 Preferentially Targets Cancer Stem Cells
- (2014) V. N. Kolev et al. CANCER RESEARCH
- Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer
- (2014) Jillian Brechbiel et al. CANCER TREATMENT REVIEWS
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
- (2014) K. P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
- (2014) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Frontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinoma
- (2014) Anna M Czarnecka et al. Future Oncology
- Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
- (2014) Carolyn D. Britten et al. INVESTIGATIONAL NEW DRUGS
- A Single Mechanism Can Explain Network-wide Insulin Resistance in Adipocytes from Obese Patients with Type 2 Diabetes
- (2014) Elin Nyman et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Fabrice André et al. LANCET ONCOLOGY
- Rapamycin promotes podocyte autophagy and ameliorates renal injury in diabetic mice
- (2014) Tangli Xiao et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Identification of mTORC2 as a Necessary Component of HRG/ErbB2-Dependent Cellular Transformation
- (2014) Miao-chong J. Lin et al. MOLECULAR CANCER RESEARCH
- Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma
- (2014) T. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
- (2014) P. Yu et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Antitumor Activity and Induction of TP53-Dependent Apoptosis toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423
- (2014) Tomoko Kashiyama et al. PLoS One
- Rapamycin Ameliorates Nephropathy despite Elevating Hyperglycemia in a Polygenic Mouse Model of Type 2 Diabetes, NONcNZO10/LtJ
- (2014) Peter C. Reifsnyder et al. PLoS One
- Mimicking caloric restriction: what about macronutrient manipulation? A response to Meynet and Ricci
- (2014) Rainer J. Klement TRENDS IN MOLECULAR MEDICINE
- The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance
- (2014) Oscar Tapia et al. VIRCHOWS ARCHIV
- A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
- (2014) B. C. Grabiner et al. Cancer Discovery
- The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
- (2014) Elisavet Paplomata et al. Therapeutic Advances in Medical Oncology
- NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro
- (2013) Wen-juan Wang et al. ACTA PHARMACOLOGICA SINICA
- Significance of mTOR Signaling and Its Inhibitor Against Cancer Stem-Like Cells in Colorectal Cancer
- (2013) Zerong Cai et al. ANNALS OF SURGICAL ONCOLOGY
- Rapamycin inhibits FBXW7 loss-induced epithelial–mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells
- (2013) Yuli Wang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014
- (2013) Kurt G. Pike et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- mTOR kinase inhibitors as potential cancer therapeutic drugs
- (2013) Shi-Yong Sun CANCER LETTERS
- Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
- (2013) Q. Liu et al. CANCER RESEARCH
- Metabolic complications with the use of mTOR inhibitors for cancer therapy
- (2013) Shanthi Sivendran et al. CANCER TREATMENT REVIEWS
- Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway
- (2013) BRUNA COROMINAS-FAJA et al. CELL CYCLE
- Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
- (2013) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR)
- (2013) Craig S. Takeuchi et al. JOURNAL OF MEDICINAL CHEMISTRY
- PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation
- (2013) Roberto Gedaly et al. JOURNAL OF SURGICAL RESEARCH
- Re: Everolimus for Angiomyolipoma Associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis (EXIST-2): A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial
- (2013) M. Pilar Laguna JOURNAL OF UROLOGY
- Synergistic Activities of MET/RON Inhibitor BMS-777607 and mTOR Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells
- (2013) J.-Y. Zeng et al. MOLECULAR CANCER THERAPEUTICS
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis
- (2013) Pengda Liu et al. NATURE CELL BIOLOGY
- The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells
- (2013) Jenna Kahn et al. NEURO-ONCOLOGY
- Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation
- (2013) Douglas D. Fang et al. PLoS One
- Mammalian Target of Rapamycin Complex 2 (mTORC2) Is a Critical Determinant of Bladder Cancer Invasion
- (2013) Sounak Gupta et al. PLoS One
- Branched Chain Amino Acid Suppresses Hepatocellular Cancer Stem Cells through the Activation of Mammalian Target of Rapamycin
- (2013) Shinobu Nishitani et al. PLoS One
- Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1
- (2013) I. Ben-Sahra et al. SCIENCE
- Quantitative Phosphoproteomics Reveal mTORC1 Activates de Novo Pyrimidine Synthesis
- (2013) A. M. Robitaille et al. SCIENCE
- A Tumor Suppressor Complex with GAP Activity for the Rag GTPases That Signal Amino Acid Sufficiency to mTORC1
- (2013) L. Bar-Peled et al. SCIENCE
- PF-04691502 triggers cell cycle arrest, apoptosis and inhibits the angiogenesis in hepatocellular carcinoma cells
- (2013) Feng-Ze Wang et al. TOXICOLOGY LETTERS
- Mechanism for the synergistic effect of rapamycin and resveratrol on hyperinsulinemia may involve the activation of protein kinase B
- (2013) J Chen et al. Cell Death & Disease
- TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists
- (2013) M V Blagosklonny Cell Death & Disease
- Resveratrol potentiates rapamycin to prevent hyperinsulinemia and obesity in male mice on high fat diet
- (2013) O V Leontieva et al. Cell Death & Disease
- mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions
- (2013) Shyuichiro Matsubara et al. Scientific Reports
- Impact of genetic alterations on mTOR-targeted cancer therapy
- (2013) Shi-Yong Sun Chinese Journal of Cancer
- Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
- (2012) B. Markman et al. ANNALS OF ONCOLOGY
- MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB
- (2012) Jose A. Martina et al. Autophagy
- Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
- (2012) A Naing et al. BRITISH JOURNAL OF CANCER
- Current approaches and future directions in the treatment of HER2-positive breast cancer
- (2012) Sara A. Hurvitz et al. CANCER TREATMENT REVIEWS
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Hepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c
- (2012) Asami Hagiwara et al. Cell Metabolism
- Yin Yang 1 Deficiency in Skeletal Muscle Protects against Rapamycin-Induced Diabetic-like Symptoms through Activation of Insulin/IGF Signaling
- (2012) Sharon M. Blättler et al. Cell Metabolism
- Temporal Changes in PTEN and mTORC2 Regulation of Hematopoietic Stem Cell Self-Renewal and Leukemia Suppression
- (2012) Jeffrey A. Magee et al. Cell Stem Cell
- mTOR Complex 1 Plays Critical Roles in Hematopoiesis and Pten-Loss-Evoked Leukemogenesis
- (2012) Demetrios Kalaitzidis et al. Cell Stem Cell
- Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies
- (2012) D. Mahadevan et al. EUROPEAN JOURNAL OF CANCER
- Adverse events associated with mTOR inhibitors
- (2012) Nicolas Pallet et al. Expert Opinion On Drug Safety
- Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer
- (2012) Sara Keck et al. Future Oncology
- Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study
- (2012) Hajime Asahina et al. INVESTIGATIONAL NEW DRUGS
- Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics
- (2012) Qingsong Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines
- (2012) Bénédicte Martin et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer
- (2012) S. Hart et al. MOLECULAR CANCER THERAPEUTICS
- mTOR Complex 2 Regulates Proper Turnover of Insulin Receptor Substrate-1 via the Ubiquitin Ligase Subunit Fbw8
- (2012) Sung Jin Kim et al. MOLECULAR CELL
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- The translational landscape of mTOR signalling steers cancer initiation and metastasis
- (2012) Andrew C. Hsieh et al. NATURE
- Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells
- (2012) M-J Jung et al. ONCOGENE
- Conditional Astroglial Rictor Overexpression Induces Malignant Glioma in Mice
- (2012) Tariq Bashir et al. PLoS One
- NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity
- (2012) Emmanouil Fokas et al. Radiation Oncology
- Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
- (2012) D. W. Lamming et al. SCIENCE
- Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo
- (2012) Yuanxi Zhu et al. TUMOR BIOLOGY
- Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2
- (2012) Lan Ye et al. Frontiers in Genetics
- Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer
- (2012) Britta Weigelt et al. Frontiers in Oncology
- Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney
- (2011) Laura R. Pearce et al. BIOCHEMICAL JOURNAL
- Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats
- (2011) N Deblon et al. BRITISH JOURNAL OF PHARMACOLOGY
- Activation of mTORC2 by Association with the Ribosome
- (2011) Vittoria Zinzalla et al. CELL
- mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway
- (2011) Timothy R. Peterson et al. CELL
- Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
- (2011) Piyush B. Gupta et al. CELL
- Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma
- (2011) Sandrine Guillard et al. CELL CYCLE
- Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
- (2011) R. Mallon et al. CLINICAL CANCER RESEARCH
- Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
- (2011) Yan-Jie Zhang et al. DRUG DISCOVERY TODAY
- Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
- (2011) Markus Gödel et al. JOURNAL OF CLINICAL INVESTIGATION
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
- (2011) Seth A. Wander et al. JOURNAL OF CLINICAL INVESTIGATION
- GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
- (2011) J. J. Wallin et al. MOLECULAR CANCER THERAPEUTICS
- PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
- (2011) J. Yuan et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
- (2011) S. V. Bhagwat et al. MOLECULAR CANCER THERAPEUTICS
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- (2011) Don Benjamin et al. NATURE REVIEWS DRUG DISCOVERY
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion
- (2011) D. Iliopoulos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state
- (2011) C. L. Chaffer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling
- (2011) Y. Yu et al. SCIENCE
- The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
- (2011) P. P. Hsu et al. SCIENCE
- Mechanisms of mTOR inhibitor resistance in cancer therapy
- (2011) Jennifer S. Carew et al. Targeted Oncology
- Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin’s Lymphoma: Results, Biology, and Development Strategies
- (2011) Jonathan H. Schatz Current Oncology Reports
- Current development of the second generation of mTOR inhibitors as anticancer agents
- (2011) Hong-Yu Zhou et al. Chinese Journal of Cancer
- A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
- (2010) Patrick B. Johnston et al. AMERICAN JOURNAL OF HEMATOLOGY
- Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy
- (2010) Xuerong Wang et al. CANCER BIOLOGY & THERAPY
- Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E
- (2010) Andrew C. Hsieh et al. CANCER CELL
- Metformin, Independent of AMPK, Inhibits mTORC1 in a Rag GTPase-Dependent Manner
- (2010) Adem Kalender et al. Cell Metabolism
- mTOR Activation Induces Tumor Suppressors that Inhibit Leukemogenesis and Deplete Hematopoietic Stem Cells after Pten Deletion
- (2010) Jae Y. Lee et al. Cell Stem Cell
- Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer
- (2010) A. Tarhini et al. CLINICAL CANCER RESEARCH
- NVP-BEZ235 as a New Therapeutic Option for Sarcomas
- (2010) M. C. Manara et al. CLINICAL CANCER RESEARCH
- The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma
- (2010) D. C. Cho et al. CLINICAL CANCER RESEARCH
- Fat Cell-Specific Ablation of Rictor in Mice Impairs Insulin-Regulated Fat Cell and Whole-Body Glucose and Lipid Metabolism
- (2010) A. Kumar et al. DIABETES
- Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy
- (2010) C. M. Contreras et al. Disease Models & Mechanisms
- Tti1 and Tel2 Are Critical Factors in Mammalian Target of Rapamycin Complex Assembly
- (2010) Takeshi Kaizuka et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of Cancer
- (2010) Qingsong Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Developmental Origins, Mechanisms, and Implications of Metabolic Syndrome
- (2010) Kimberley D. Bruce et al. JOURNAL OF NUTRITION
- WJD008, a Dual Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin Inhibitor, Prevents PI3K Signaling and Inhibits the Proliferation of Transformed Cells with Oncogenic PI3K Mutant
- (2010) T. Li et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
- (2010) Katharine A. Price et al. Journal of Thoracic Oncology
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
- (2010) T E Witzig et al. LEUKEMIA
- Antitumor Efficacy Profile of PKI-402, a Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor
- (2010) Robert Mallon et al. MOLECULAR CANCER THERAPEUTICS
- Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
- (2010) Darcy A. Krueger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer
- (2010) T Sato et al. ONCOGENE
- Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
- (2010) C A Sparks et al. ONCOGENE
- Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer
- (2010) Colby L. Eaton et al. PROSTATE
- mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
- (2010) R. J. O. Dowling et al. SCIENCE
- Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
- (2010) Steven D. Knight et al. ACS Medicinal Chemistry Letters
- The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential
- (2009) Hiroyuki Mori et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
- (2009) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice
- (2009) M. G. Kharas et al. BLOOD
- LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
- (2009) C L Mahoney et al. BRITISH JOURNAL OF CANCER
- Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
- (2009) P Cao et al. BRITISH JOURNAL OF CANCER
- mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
- (2009) David A. Guertin et al. CANCER CELL
- Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
- (2009) D. W. McMillin et al. CANCER RESEARCH
- Differential Destruction of Stem Cells: Implications for Targeted Cancer Stem Cell Therapy
- (2009) M. E. Sehl et al. CANCER RESEARCH
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
- (2009) K. Yu et al. CANCER RESEARCH
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
- (2009) Timothy R. Peterson et al. CELL
- Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation
- (2009) Jean-François Tanti et al. CURRENT OPINION IN PHARMACOLOGY
- The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer☆☆☆
- (2009) Virginia Tirino et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- Combined Targeted Treatment to Eliminate Tumorigenic Cancer Stem Cells in Human Pancreatic Cancer
- (2009) Maria–Theresa Mueller et al. GASTROENTEROLOGY
- Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis
- (2009) Josep Castellvi et al. HUMAN PATHOLOGY
- ULK1·ATG13·FIP200 Complex Mediates mTOR Signaling and Is Essential for Autophagy
- (2009) Ian G. Ganley et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
- (2009) Carson C. Thoreen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
- (2009) David A. Reardon et al. JOURNAL OF NEURO-ONCOLOGY
- Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1
- (2009) C. C. Dibble et al. MOLECULAR AND CELLULAR BIOLOGY
- mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling
- (2009) L.-A. Julien et al. MOLECULAR AND CELLULAR BIOLOGY
- Nutrient-dependent mTORC1 Association with the ULK1–Atg13–FIP200 Complex Required for Autophagy
- (2009) Nao Hosokawa et al. MOLECULAR BIOLOGY OF THE CELL
- ULK-Atg13-FIP200 Complexes Mediate mTOR Signaling to the Autophagy Machinery
- (2009) Chang Hwa Jung et al. MOLECULAR BIOLOGY OF THE CELL
- Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors
- (2009) R. Marone et al. MOLECULAR CANCER RESEARCH
- NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
- (2009) T.-J. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
- (2009) David E. Harrison et al. NATURE
- Molecular mechanisms of mTOR-mediated translational control
- (2009) Xiaoju Max Ma et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair
- (2009) M -A Westhoff et al. ONCOGENE
- mTOR complex 2 in adipose tissue negatively controls whole-body growth
- (2009) N. Cybulski et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
- (2009) Saskia M. Brachmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)
- (2008) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells
- (2008) Ville Hietakangas et al. BMC CANCER
- Class I PI3 Kinase Inhibition by the Pyridinylfuranopyrimidine Inhibitor PI-103 Enhances Tumor Radiosensitivity
- (2008) R. Prevo et al. CANCER RESEARCH
- Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging
- (2008) C. R. Schnell et al. CANCER RESEARCH
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- A Stochastic Model for Cancer Stem Cell Origin in Metastatic Colon Cancer
- (2008) C. Odoux et al. CANCER RESEARCH
- Adipose-Specific Knockout of raptor Results in Lean Mice with Enhanced Mitochondrial Respiration
- (2008) Pazit Polak et al. Cell Metabolism
- 250 ORAL OXA-01, a novel potent mTORC1/TORC2 kinase inhibitor, demonstrates broad spectrum antitumor activity in preclinical models of human cancer
- (2008) P.C. Gokhale et al. EJC SUPPLEMENTS
- The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma
- (2008) Philipp Baumann et al. EXPERIMENTAL CELL RESEARCH
- Deforolimus (AP23573) a novel mTOR inhibitor in clinical development
- (2008) Monica Mita et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- mTOR inhibitors in the treatment of cancer
- (2008) Angelica Fasolo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- S6 Kinase 1 Regulates Estrogen Receptor α in Control of Breast Cancer Cell Proliferation
- (2008) Rachel L. Yamnik et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro
- (2008) Silvia Darb-Esfahani et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
- (2008) Arkaitz Carracedo et al. JOURNAL OF CLINICAL INVESTIGATION
- A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)
- (2008) Teri N. Kreisl et al. JOURNAL OF NEURO-ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
- (2008) S Park et al. LEUKEMIA
- A Rictor-Myo1c Complex Participates in Dynamic Cortical Actin Events in 3T3-L1 Adipocytes
- (2008) G. N. Hagan et al. MOLECULAR AND CELLULAR BIOLOGY
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- PKBα/Akt1 Acts Downstream of DNA-PK in the DNA Double-Strand Break Response and Promotes Survival
- (2008) Lana Bozulic et al. MOLECULAR CELL
- AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
- (2008) Dana M. Gwinn et al. MOLECULAR CELL
- Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation
- (2008) Wei Guo et al. NATURE
- Regulation of TORC1 by Rag GTPases in nutrient response
- (2008) Eunjung Kim et al. NATURE CELL BIOLOGY
- Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies
- (2008) T. E. Hutson et al. ONCOLOGIST
- mTORC1 promotes survival through translational control of Mcl-1
- (2008) J. R. Mills et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations
- (2008) A. Dubrovska et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More